Company intelligence / Profile preview

Eurand

Bridgewater Township, New Jersey, United States

Ownership: Private
Employees: ~500
Development stage: Other

Overview

Eurand developed and commercialized enhanced and specialty pharmaceutical products, most notably ZENPEP (pancrelipase) for exocrine pancreatic insufficiency, and several extended-release formulations of oral drugs including successful co-developed assets; at acquisition it had multiple products on market and late-stage pipeline assets targeting GI and pediatric diseases.

Therapeutic areas: GastroenterologyNeurologyPulmonology
Modalities: Small moleculeBiologicPancrelipase (biologic enzyme product)Extended-release formulations
Industry: Biotech

Partnerships

Cephalon (for AMRIX)Chiesi Pharmaceutici SpA (CLIPPER licensee in EU)Chattem (UNISOM Sleep Melts, OTC partner)

Beyond the preview

Go deeper on Eurand.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eurand.

Explore the full profile